STAT5A

Signal transducer and activator of transcription 5A · P42229 · STAT5A on Sugi Atlas →

8,000 patent compounds predicted against STAT5A, 5,696 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL4050277 SCHEMBL4050277 0.37 4/20
SCHEMBL4053125 SCHEMBL4053125 0.36 4/20
SCHEMBL1902159 SCHEMBL1902159 0.71 3/20
SCHEMBL3191116 SCHEMBL3191116 0.41 3/20
SCHEMBL4053522 SCHEMBL4053522 0.38 3/20
SCHEMBL4060306 SCHEMBL4060306 0.37 3/20
SCHEMBL4061326 SCHEMBL4061326 0.37 3/20
SCHEMBL3816117 SCHEMBL3816117 0.36 3/20
Suramin Suramin (SCHEMBL414636) 1.00 2/20
SCHEMBL4027006 SCHEMBL4027006 0.50 2/20
SCHEMBL4110670 SCHEMBL4110670 0.46 2/20
SCHEMBL1290921 SCHEMBL1290921 0.45 2/20
SCHEMBL1514687 SCHEMBL1514687 0.44 2/20
SCHEMBL478382 SCHEMBL478382 0.43 2/20
SCHEMBL2382748 SCHEMBL2382748 0.43 2/20
SCHEMBL3058685 SCHEMBL3058685 0.43 2/20
SCHEMBL3699919 SCHEMBL3699919 0.43 2/20
SCHEMBL3383187 SCHEMBL3383187 0.42 2/20
SCHEMBL478250 SCHEMBL478250 0.40 2/20
SCHEMBL3895096 SCHEMBL3895096 0.40 2/20

Clinical trials — most relevant to STAT5A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial PHASE2/PHASE3UNKNOWN
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation PHASE1/PHASE2COMPLETED
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia PHASE2COMPLETED
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus PHASE1/PHASE2WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients PHASE1RECRUITING
Itacitinib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis PHASE1COMPLETED
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED
STAT4 in Multiple Sclerosis by PCR and Flow Cytometry nanCOMPLETED
CircularRNA-microRNA-mRNA Regulatory Axis in IVF nanNOT_YET_RECRUITING
Cutaneous JAK in Vitiligo and Acne Vulgaris. nanUNKNOWN
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
Androgenetic Alopecia and the JAK-STAT Pathway nanCOMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study nanWITHDRAWN
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Ruxolitinib in Patients With Myelofibrosis nanUNKNOWN
Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells nanRECRUITING
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders nanRECRUITING
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases nanNOT_YET_RECRUITING
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma nanCOMPLETED
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria nanCOMPLETED
Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STAT5A binder may also engage these)

ProteinNameSimilarity
Q9TUZ1 1.000 Q9TUZ1 →
P42230 1.000 P42230 →
Q9TUM3 1.000 Q9TUM3 →
STAT5B Signal transducer and activator of transcription 5B 1.000 landscape →
Q62771 1.000 Q62771 →
Q95115 1.000 Q95115 →
Q9TUZ0 1.000 Q9TUZ0 →
P52632 1.000 P52632 →
P42232 1.000 P42232 →
P42231 0.999 P42231 →
P52631 0.976 P52631 →
P42227 0.975 P42227 →
P61635 0.973 P61635 →
STAT1 Signal transducer and activator of transcription 1-alpha/beta 0.973 landscape →
Q6DV79 0.972 Q6DV79 →
Q9PVX8 0.971 Q9PVX8 →
STAT3 Signal transducer and activator of transcription 3 0.969 landscape →
Q19S50 0.967 Q19S50 →
Q6ZUT9 0.965 Q6ZUT9 →
Q9ERA0 0.965 Q9ERA0 →
Q8IZD9 0.965 Q8IZD9 →
Q764M5 0.964 Q764M5 →
A6QL63 0.963 A6QL63 →
Q6NZH6 0.963 Q6NZH6 →
A2RSQ0 0.962 A2RSQ0 →
RPTOR Regulatory-associated protein of mTOR 0.961 landscape →
Q9Y4J8 0.961 Q9Y4J8 →
Q6GQW0 0.960 Q6GQW0 →
Q7ZXK3 0.960 Q7ZXK3 →
Q8CIQ7 0.960 Q8CIQ7 →